Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Oncolym: Began Phase I study

September 25, 2000 7:00 AM UTC

Techniclone Corp. (TCLN), Tustin, Calif. Product: Oncolym Business: Cancer Therapeutic category: Antibody, Cytotoxic Target: HLA-dr on B cells Description: Radiolabeled murine Lym-1 monoclonal antibo...